

Award Number: W81XWH-12-1-0596

TITLE: Examination of the mGluR-mTOR Pathway for the Identification of Potential Therapeutic Targets To Treat Fragile X

PRINCIPAL INVESTIGATOR: Thomas A. Jongens, Ph.D.

CONTRACTING ORGANIZATION: Trustees of the University of Pennsylvania
Philadelphia, PA 19104

REPORT DATE: October 2015

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2015		2. REPORT TYPE Annual		3. DATES COVERED 30 Sep 2014 - 29 Sep 2015	
4. TITLE AND SUBTITLE Examination of the mGluR-mTOR Pathway for the Identification of Potential Therapeutic Targets To Treat Fragile X				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0596	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Thomas A. Jongens, Ph.D. E-Mail: jongens@mail.med.upenn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Perelman School of Medicine Trustees of the University of Pennsylvania Pamela Caudill 3451 Walnut St Philadelphia, PA 19104-6205				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Fragile X Syndrome (FXS) is a single gene disorder caused by loss of <i>FMR1</i> gene function. This disease leads to cognitive impairment and is the most common genetic cause of autism, accounting for 2-6% of all diagnosed cases (Hagerman et al 2008). In previous studies of a <i>Drosophila</i> model for FXS, we identified pharmacological treatments that rescued phenotypes relevant to this syndrome such as social, neuroanatomical and cognitive deficits (McBride et al., 2005; Choi et al., 2010). These results have been translated to the mouse model of FXS leading to the impetus to initiate clinical trials with Fragile X patients (Yan et al., 2005; Dolen et al., 2007; de Vrij et al., 2008; Choi et al., 2011). The fact that clinical trials of two distinct compounds identified in flies and tested in mice have reported some level of efficacy highlights the relevance of <i>Drosophila</i> and mouse-based disease modeling to identify potential treatments for developmental brain disorders and other diseases (Berry-Kravis et al., 2008; Berry-Kravis et al., 2009; Berry-Kravis et al., 2011). Our identification of the novel compounds that first identified in flies and tested in mice have reported some level of efficacy highlights the relevance of <i>Drosophila</i> and mouse-based disease modeling to identify potential treatments for developmental brain disorders and other diseases (Berry-Kravis et al., 2008; Berry-Kravis et al., 2009; Berry-Kravis et al., 2011).					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	14	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	3
Body.....	3
Reportable Outcomes.....	4
Key Research Accomplishments.....	7
Conclusion.....	8
References.....	9
Appendices.....	N/A

Introduction

Fragile X syndrome is the leading cause of intellectual disability resulting from a single gene mutation. Previously, we characterized social and cognitive impairments in a *Drosophila* model of Fragile X syndrome and demonstrated that these impairments were rescued by treatment with metabotropic glutamate receptor (mGluR) antagonists or lithium. In the mouse model of Fragile X a well-characterized phenotype is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Last year we have reported the use of PDE-4 inhibitors in rescuing social, and memory phenotypes in the mouse as well as the enhanced-LTD phenotype observed in the *Fmr1* mouse KO. Last year we also reported the finding that metformin treatment also rescues the memory phenotype in the fly model of Fragile X. In this year we have focused on metformin treatment in the fly model and prepared to perform metformin treatment in the mouse to determine if it can also rescue memory and other phenotypes in the mouse model.

Metformin is an important drug to test in the fly and mouse models of Fragile X. Most importantly, metformin is an FDA approved drug that has a very safe and long clinical history. It is commonly used to treat type II diabetes in humans and has recently been used to treat weight gain in patients treated with anti-psychotics. It is safe enough to prescribe to children and is now routinely prescribed to children as young as 5 years of age both to control weight gain and to treat type II diabetes. If metformin is effective in the fly and mouse model, clinical trials with Fragile X patients would clearly be warranted.

There are two known targets of metformin action that should help ameliorate the increased insulin signaling that we observed in our Fragile X fly model. First metformin is known to increase the activity of AMPK. AMPK is a known activator of the TSC1/II complex that represses Rheb activity. Since Rheb is a known activator of mTOR, the increased activation of AMPK should result in a decrease in mTOR activity (Figure 1). Another activity that metformin has is the transcriptional activation of PTEN, increasing PTEN activity levels. PTEN antagonizes PI3K activity which reduces the activation of mTOR (Figure 1). Thus both activities of metformin should correct the increased signaling observed in the fly fragile X model.





Figure 1. Insulin, mTOR signaling pathway the activity of metformin. Metformin has two activities that act to reduce mTOR signaling activity. First it acts to activate AMPK which increases the activity of the TSC1/II complex and represses Rheb activity more, thus activating mTOR less. Metformin also activates the transcription of PTEN, which results in increased repression of PI3K and less activation of Akt and thus less repression of Tsc1/II and again adding to the repression of Rheb and thus less activation of mTOR.

Reportable outcomes:

Task 8

To study the efficacy of metformin in more detail, we have tested the effect of treating *dfmr1* mutants during development, during adulthood or both and tested for short-term memory as well as for rescue of circadian behavior. We have found that even with adult treatment alone we can rescue the memory phenotype in the *dfmr1* mutant. We however could not rescue the circadian defect, however we feel that this is due to an accessibility problem. In temporal experiments we have found that *dfmr1* activity is required during pupal development for proper circadian regulation. Unfortunately we currently cannot provide the drug treatment during the pupal period (the flies/larvae do not eat and are covered by a hard shell) and have enough adults hatch to test for circadian behavior. Nonetheless the success that we have had in rescuing memory warrants testing in the mouse Fragile X model.

Effect on Circadian Behavior:



Effect on Courtship-Based Memory:




Figure 2. Effect of developmental and adulthood metformin treatment on circadian behavior and courtship-based memory. a-b, The circadian behavior of flies raised on a, 30 μ M or b, 100 μ M metformin and moved to 1mM metformin or vehicle control food within 24 hour of eclosion was examined. Metformin treatment did not improve the rhythmicity of *dfmr1* mutants. c-d, Flies raised on c, 30 μ M metformin or d, 100 μ M metformin and moved to 1mM metformin or vehicle control food within 24 hours of eclosion were tested in the conditioned courtship paradigm. Treatment with either 30 μ M or 100 μ M metformin in development alone, or paired with 1mM metformin treatment in adulthood rescued STM in *dfmr1* mutant flies. Both MIs and CIs are displayed for each experiment. N ranged between 17-27.

Task 13

To prepare for studies to determine the efficacy of metformin treatment in the mouse we have tested the effect of a high dose of metformin on mice to determine how well it is tolerated and if there are any adverse side effects. As shown in Figure 3 we observed that the *dfmr1* maintain a relatively normal weight profile during from weaning and well into adulthood.




Figure 3. Effect of high dose metformin on *Fmr1* KO and control mice to determine how well the drug is tolerated. We find that mice that were given a high dose of metformin (2.0mg/ml) (a comparable dose for type II diabetes patients would be 200mg/ml) maintain normal weight and do not show any obvious negative effects of metformin treatment. The mice were placed on metformin at 4 weeks of age.

continued studies for Task 12

To prepare for testing the mice for rescue of phenotypes with metformin, we have obtained reproducible phenotypes with the novel object recognition test, the rotorod with several protocols and we have also noted a significant hypoactivity phenotype in the *Fmr1* KO mice during their active phase.




Figure 4. The *Fmr1* KO mice display a deficit in the novel object recognition task. In this assay mice are habituated to a chamber that contains two objects for several trials. The following day one of the objects is replaced with a novel object. Control mice display a significant exploratory preference for the novel object. The *Fmr1*KO mice display a significantly reduced preference for the novel object displaying a reduced memory of the two initial objects in the chamber. This task is dependent on hippocampal and perirhinal cortex function, and the *Dfmr1* mutants display a reproducible memory deficit in this task.

We have also established a reproduced a locomotor memory deficit in the rotarod test (Figure 5). We have found that in a test where mice are give three trials a day for three consecutive days that the *Fmr1* KO mice fail to continue to learn to stay on the rod during trials during days 2 and 3. This task requires a combination of cerebellar and hippocampal function (Figure 5).






Figure 5. *Fmr1* KO mice display reduced locomotor learning in the rotorod assay.

In activity monitoring of the *Fmr1* KO and control mice, we have observed that the *Fmr1* KO mice display an activity deficit during their active phase (night time) relative to control mice. Although this is not a cognitive task, we will explore what effect metformin treatment has on this phenotype.

Novel Finding not listed in original tasks



Key Research Accomplishments:

Task 8- We have completed timeline testing for metformin treatment of the *dfmr1* mutants and have found that adult only treatment is sufficient to rescue the memory phenotype with both courtship conditioning and olfactory based memory testing.

Task 12. Continued development of cognitive and behavioral phenotypes to test the efficacy of drug treatments. We also currently have *Fmr1* KO and control mice on metformin and will be testing their abilities on the rotorod and in the novel object recognition assay shortly, see 13c.

Ongoing tasks:

Task 1c. Perform biochemical analysis to determine effects of PDE-4 inhibition on PI3K and Akt activity and smRP6 levels.

Using an elisa assay to quantitate cAMP levels, we have now established that the *dfmr1* mutants have reduced resting levels of cAMP. We have also determined that treatment with rolipram can rescue the deficit of cAMP. Therefore we are in a position to now examine the effect of PDE-4 inhibition on PI3K, Akt and smRP6 levels.

We are also initiating biochemical tests to determine the effect that metformin treatment has on the insulin-signaling pathway of the *dfmr1* mutants. We expect that we will observe increased levels of p-AMPK (activated AMPK), decreased activity of S6K which is downstream of mTOR and is the next proximal antibody that we can use (Figure 1) in *Drosophila*. We will also

determine the levels small ribosomal protein 6 whose expression is regulated by the mTOR pathway. Increased mTOR activity leads to increase smRP6 levels. Also to examine the effect on PTEN activity, we will determine whether metformin treatment also reduces Akt levels (e.g. p-Akt).

8a. Examine naïve courtship, learning during training and memory in *dfmr1* mutants and controls treated with AICAR and vehicle during development alone, adulthood alone and during both times. This ongoing test will provide validation for the efficacy of metformin, as AICAR also activates AMPK activity.

12c. Perform behavioral testing battery on *FMR1* KO and control mice.

13c. Perform behavioral testing on *FMR1* KO and control mice that are treated with metformin or vehicle.

Manuscripts Accepted:

1) [Deciphering discord: How Drosophila research has enhanced our understanding of the importance of FMRP in different spatial and temporal contexts.](#) Weisz ED, Monyak RE, Jongens TA. Exp Neurol. 2015 May 28. pii: S0014-4886(15)30001-7. doi: 10.1016/j.expneurol.2015.05.015. [Epub ahead of print] Review. PMID: 26026973

2) [Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome.](#) Gross C, Chang CW, Kelly SM, Bhattacharya A, McBride SM, Danielson SW, Jiang MQ, Chan CB, Ye K, Gibson JR, Klann E, Jongens TA, Moberg KH, Huber KM, Bassell GJ. Cell Rep. 2015 May 5;11(5):727-36. doi: 10.1016/j.celrep.2015.03.060. Epub 2015 Apr 23. PMID: 25921541

3) [PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.](#) Choi CH, Schoenfeld BP, Weisz ED, Bell AJ, Chambers DB, Hinchey J, Choi RJ, Hinchey P, Kollaros M, Gertner MJ, Ferrick NJ, Terlizzi AM, Yohn N, Koenigsberg E, Liebelt DA, Zukin RS, Woo NH, Tranfaglia MR, Louneva N, Arnold SE, Siegel SJ, Bolduc FV, McDonald TV, Jongens TA, McBride SM. J Neurosci. 2015 Jan 7;35(1):396-408. doi: 10.1523/JNEUROSCI.1356-12.2015. PMID: 25568131

4) [Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1.](#) Wolman MA, de Groh ED, McBride SM, Jongens TA, Granato M, Epstein JA. Cell Rep. 2014 Sep 11;8(5):1265-70. doi: 10.1016/j.celrep.2014.07.054. Epub 2014 Aug 28. PMID: 25176649

Papers under revision:

Insulin Misregulation underlies Behavioral and Cognitive Deficits in a *Drosophila* Fragile X Model Monyak, R., Emerson, D, Zheng, X., Schoenfeld, B., McBride, S.M.J, Sehgal, A., and Jongens, T.A.

Conclusions:

The overall objective of the work we have accomplished so far was to examine the efficacy of pharmacologically inhibiting PDE-4 activity to correct synaptic plasticity impairments in the fly and

mouse models of Fragile X syndrome. Now we have added metformin to the treatment testing. Since metformin has a much better clinical history than any recently FDA approved PDE-4 inhibitors, we have reprioritized our studies to focus on the efficacy of metformin treatment on the fly and mouse fragile X models. The *Drosophila* Fragile X model recapitulates the most debilitating aspect of the disease in humans, namely impaired cognitive function. In our further dissection of the proteins involved in the mGluR signaling cascade, we have identified metformin as a potential therapy for treatment of Fragile X. The data from the fly model indicate that this drug can rescue several memory phenotypes displayed by the *dfmr1* mutant and this is with adult only treatment. This is important as this indicates that by changing the physiology of the *dfmr1* mutants we can rescue memory. We are currently moving to test whether metformin treatment can rescue the locomotor and novel object recognition task deficits that we have established with the *Fmr1* KO mice. If we can successfully rescue these or other cognitive tasks with the *Fmr1* KO mouse, this will provide necessary data to warrant clinical testing with Fragile X patients.

References:

- Akins MR, Berk-Rauch HE, Fallon JR (2009) Presynaptic translation: stepping out of the postsynaptic shadow. *Front Neural Circuits* 3:17.
- Bailey CP, Nicholls RE, Zhang XL, Zhou ZY, Muller W, Kandel ER, Stanton PK (2008) Galpha(i2) inhibition of adenylate cyclase regulates presynaptic activity and unmasks cGMP-dependent long-term depression at Schaffer collateral-CA1 hippocampal synapses. *Learn Mem* 15:261-270.
- Bakker CE, Oostra BA (2003) Understanding fragile X syndrome: insights from animal models. *Cytogenet Genome Res* 100:111-123.
- Banerjee P, Schoenfeld BP, Bell AJ, Choi CH, Bradley MP, Hinchey P, Kollaros M, Park JH, McBride SM, Dockendorff TC (2010) Short- and long-term memory are modulated by multiple isoforms of the fragile X mental retardation protein. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 30:6782-6792.
- Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. *Proc Natl Acad Sci U S A* 95:15020-15025.
- Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. *Trends Neurosci* 27:370-377.
- Berry-Kravis E, Huttenlocher PR (1992) Cyclic AMP metabolism in fragile X syndrome. *Ann Neurol* 31:22-26.
- Berry-Kravis E, Sklena P (1993) Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. *Am J Med Genet* 45:81-87.
- Berry-Kravis E, Ciurlionis R (1998) Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells. *J Neurosci Res* 51:41-48.
- Berry-Kravis E, Hicar M, Ciurlionis R (1995) Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. *Pediatr Res* 38:638-643.
- Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT (2008) Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. *J Dev Behav Pediatr* 29:293-302.
- Bhogal B, Jongens TA (2011) Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention. *Dis Model Mech*.
- Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *J Med Genet* 46:94-102.
- Bolduc FV, Bell K, Cox H, Broadie KS, Tully T (2008) Excess protein synthesis in *Drosophila* fragile X mutants impairs long-term memory. *Nat Neurosci* 11:1143-1145.
- Byers D, Davis RL, Kiger JA, Jr. (1981) Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in *Drosophila melanogaster*. *Nature* 289:79-81.
- Choi CH, Schoenfeld BP, Bell AJ, Hinchey P, Kollaros M, Gertner MJ, Woo NH, Tranfaglia MR, Bear MF, Zukin RS, McDonald TV, Jongens TA, McBride SM (2011) Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment. *Brain research* 1380:106-119.
- Choi CH, McBride SM, Schoenfeld BP, Liebelt DA, Ferreira D, Ferrick NJ, Hinchey P, Kollaros M, Rudominer RL, Terlizzi AM, Koenigsberg E, Wang Y, Sumida A, Nguyen HT, Bell AJ, McDonald TV, Jongens TA (2010) Age-dependent cognitive impairment in a *Drosophila* fragile X model and its pharmacological rescue. *Biogerontology* 11:347-362.
- Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH (2007) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. *Neuropsychopharmacology* 32:2393-2404.

- Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F (2010) Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. *Neurodegener Dis* 7:96-98.
- Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* 146:247-261.
- Davis RL, Kiger JA, Jr. (1981) Dunce mutants of *Drosophila melanogaster*: mutants defective in the cyclic AMP phosphodiesterase enzyme system. *J Cell Biol* 90:101-107.
- Davis RL, Takayasu H, Eberwine M, Myres J (1989) Cloning and characterization of mammalian homologs of the *Drosophila dunce*⁺ gene. *Proc Natl Acad Sci U S A* 86:3604-3608.
- Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, Sehgal A, Jongens TA (2002) *Drosophila* lacking *dfmr1* activity show defects in circadian output and fail to maintain courtship interest. *Neuron* 34:973-984.
- Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. *Neuron* 56:955-962.
- Dudai Y, Jan YN, Byers D, Quinn WG, Benzer S (1976) *dunce*, a mutant of *Drosophila* deficient in learning. *P Natl Acad Sci USA* 73:1684-1688.
- Dujardin F (1850) Memoire sur le systeme nerveux des insectes. *Ann. Sci. Nat. Zool.*
- Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proc Natl Acad Sci U S A* 97:11960-11965.
- Garcia-Alloza M, Prada C, Lattarulo C, Fine S, Borrelli LA, Betensky R, Greenberg SM, Frosch MP, Bacskaï BJ (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. *J Neurochem* 109:1636-1647.
- Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. *J Clin Invest* 114:1624-1634.
- Gross C, Berry-Kravis EM, Bassell GJ (2012) Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. *Neuropsychopharmacology* 37:178-195.
- Hagerman PJ (2008) The fragile X prevalence paradox. *J Med Genet* 45:498-499.
- Hagerman R, Lauterborn J, Au J, Berry-Kravis E (2012) Fragile X syndrome and targeted treatment trials. Results and problems in cell differentiation 54:297-335.
- Henkel-Tigges J, Davis RL (1990) Rat homologs of the *Drosophila dunce* gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724. *Mol Pharmacol* 37:7-10.
- Hou J, Kuromi H, Fukasawa Y, Ueno K, Sakai T, Kidokoro Y (2004) Repetitive exposures to nicotine induce a hyper-responsiveness via the cAMP/PKA/CREB signal pathway in *Drosophila*. *Journal of neurobiology* 60:249-261.
- Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E (2006) Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. *Neuron* 51:441-454.
- Huber KM, Kayser MS, Bear MF (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. *Science* 288:1254-1257.
- Huber KM, Roder JC, Bear MF (2001) Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. *J Neurophysiol* 86:321-325.
- Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc Natl Acad Sci U S A* 99:7746-7750.
- Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA (2007) Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. *Lancet Neurol* 6:45-55.
- Joiner ML A, Griffith LC (1997) CaM kinase II and visual input modulate memory formation in the neuronal circuit controlling courtship conditioning. *J Neurosci* 17:9384-9391.
- Kamyshev NG, Iliadi KG, Bragina JV (1999) *Drosophila* conditioned courtship: two ways of testing memory. *Learn Mem* 6:1-20.

- Kane NS, Robichon A, Dickinson JA, Greenspan RJ (1997) Learning without performance in PKC-deficient *Drosophila*. *Neuron* 18:307-314.
- Kelleher RJ, 3rd, Govindarajan A, Tonegawa S (2004) Translational regulatory mechanisms in persistent forms of synaptic plasticity. *Neuron* 44:59-73.
- Kelley DJ, Davidson RJ, Elliott JL, Lahvis GP, Yin JC, Bhattacharyya A (2007) The cyclic AMP cascade is altered in the fragile X nervous system. *PLoS ONE* 2:e931.
- Krueger DD, Bear MF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. *Annual review of medicine* 62:411-429.
- Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA (2000) Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3 β . *Mol Cell Biol* 20:9356-9363.
- Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. *Curr Biol* 15:1961-1967.
- Liu ZH, Chuang DM, Smith CB (2011) Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. *Int J Neuropsychopharmacol* 14:618-630.
- Malenka RC, Bear MF (2004) LTP and LTD: an embarrassment of riches. *Neuron* 44:5-21.
- Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V (2004) Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. *Life Sci* 75:823-840.
- McBride SM, Bell AJ, Jongens TA (2012) Behavior in a *Drosophila* model of fragile X. Results and problems in cell differentiation 54:83-117.
- McBride SM, Giuliani G, Choi C, Krause P, Correale D, Watson K, Baker G, Siwicki KK (1999) Mushroom body ablation impairs short-term memory and long-term memory of courtship conditioning in *Drosophila melanogaster*. *Neuron* 24:967-977.
- McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreira D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA (2005) Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a *Drosophila* model of fragile X syndrome. *Neuron* 45:753-764.
- Michel CI, Kraft R, Restifo LL (2004) Defective neuronal development in the mushroom bodies of *Drosophila* fragile X mental retardation 1 mutants. *J Neurosci* 24:5798-5809.
- Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP (2009) Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. *Neuropharmacology* 56:463-472.
- Mines MA, Jope RS (2011) Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. *Frontiers in molecular neuroscience* 4:35.
- Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS (2010) GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. *PLoS ONE* 5:e9706.
- Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, Nelson DL, Hassan BA (2002) *Drosophila* fragile X protein, DFXR, regulates neuronal morphology and function in the brain. *Neuron* 34:961-972.
- Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH (2009) Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. *FASEB J* 23:739-750.
- Nosyreva ED, Huber KM (2006) Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. *J Neurophysiol* 95:3291-3295.
- O'Kane CJ (2011) *Drosophila* as a model organism for the study of neuropsychiatric disorders. *Current topics in behavioral neurosciences* 7:37-60.

- Oger S, Mehats C, Dallot E, Cabrol D, Leroy MJ (2005) Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. *J Immunol* 174:8082-8089.
- Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW (2010) Open-label add-on treatment trial of minocycline in fragile X syndrome. *BMC neurology* 10:91.
- Pascual A, Preat T (2001) Localization of long-term memory within the *Drosophila* mushroom body. *Science* 294:1115-1117.
- Raymond FL, Tarpey P (2006) The genetics of mental retardation. *Hum Mol Genet* 15 Spec No 2:R110-116.
- Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, Garcia-Merino A (2005) Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. *J Neuroimmunol* 168:13-20.
- Santschi LA, Zhang XL, Stanton PK (2006) Activation of receptors negatively coupled to adenylate cyclase is required for induction of long-term synaptic depression at Schaffer collateral-CA1 synapses. *J Neurobiol* 66:205-219.
- Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004) Inhibitory effects of group II mGluR-related drugs on memory performance in mice. *Physiol Behav* 80:747-758.
- Siegel RW, Hall JC (1979) Conditioned responses in courtship behavior of normal and mutant *Drosophila*. *Proc Natl Acad Sci U S A* 76:3430-3434.
- Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R (2006) Exaggerated behavioral phenotypes in *Fmr1/Fxr2* double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. *Hum Mol Genet* 15:1984-1994.
- Tanji C, Yamamoto H, Yorioka N, Kohno N, Kikuchi K, Kikuchi A (2002) A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. *J Biol Chem* 277:36955-36961.
- Tessier CR, Broadie K (2012) Molecular and genetic analysis of the *Drosophila* model of fragile X syndrome. *Results and problems in cell differentiation* 54:119-156.
- Walsh CA, Morrow EM, Rubenstein JL (2008) Autism and brain development. *Cell* 135:396-400.
- Wang LW, Berry-Kravis E, Hagerman RJ (2010) Fragile X: leading the way for targeted treatments in autism. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics* 7:264-274.
- Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology* 49:1053-1066.
- Yuskaitis CJ, Beurel E, Jope RS (2010a) Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. *Biochim Biophys Acta* 1802:1006-1012.
- Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS (2010b) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. *Biochem Pharmacol* 79:632-646.
- Zars T, Fischer M, Schulz R, Heisenberg M (2000) Localization of a short-term memory in *Drosophila*. *Science* 288:672-675.
- Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K (2001) *Drosophila* fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. *Cell* 107:591-603.